Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
WEST LAFAYETTE, Ind., Nov. 02, 2016 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 9th, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
